Thyme Care Hits $2 Billion Valuation in $125 Million Series E, Reorganizes Under New Parent Entity

Oncology navigation platform Thyme Care has closed a $125 million Series E investment round at a valuation exceeding $2 billion, as first reported by CNBC Technology. The fresh capital influx approximately doubles the startup's market valuation relative to its Series D financing round completed less than a year ago.

Morgan Health led the round, which featured participation from corporate healthcare investors Humana and CVS Health Ventures. Existing and additional backers joining the transaction included AlleyCorp, HealthQuest Capital, and a16z Bio + Health. Alongside the raise, the startup announced the formation of a new parent organisation named Thyme Companies, designed to incubate and manage specialized business units addressing systemic gaps in oncology treatment, administration, and payment models.

Under the new corporate structure, Thyme Care co-founder Robin Shah has assumed the role of executive chairman at Thyme Companies. Shah previously stepped down as chief executive officer of Thyme Care in July, handing operational leadership to Brad Diephuis, who previously served as the company's president and chief operating officer. Shah established the business six years ago alongside co-founder Bobby Green to address unserved operational needs in cancer care, specifically patient support required between clinical appointments.

Thyme Care's virtual navigation system connects cancer patients with dedicated guidance to manage care plans, administrative requirements, and symptom tracking outside standard hospital visits. The company currently covers more than 10.5 million individuals across all 50 U.S. states and manages over $7 billion in total oncology spend. The platform generated more than $125 million in revenue last year, reflecting a fivefold increase over the preceding twelve-month period.

The initial operational focus for Thyme Companies will center on reducing prescription cancer drug costs. The entity plans to partner with health plans and medical providers to accelerate the adoption of lower-cost biosimilar medications—clinically equivalent alternatives to biologic treatments. Shah noted that biosimilars have historically struggled to deliver promised financial savings to patients, presenting an opportunity for targeted administrative interventions.

A second immediate priority for the parent organization involves streamlining access to clinical trials. By addressing logistical and enrollment bottlenecks that frequently delay drug development, Thyme Companies aims to broaden patient entry into experimental treatment programs. The firm expects to launch the first of these new business entities later this year.

Financially, Thyme Care has reached profitability and is generating positive free cash flow. Shah confirmed the enterprise possesses a strong balance sheet to pursue strategic hires and potential corporate acquisitions. While the company holds no near-term plans for an initial public offering, management intends to continue evaluating both private and public financing avenues to support its long-term growth objectives.